The His Optimised Pacing Evaluated for Heart Failure Trial (HOPE-HF).

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

Also called NCT02671903

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02671903
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02671903. Randomized; double masking; primary purpose treatment. Start 2016-01 (actual); primary completion 2020-10-31 (actual). Results posted on 2025-02-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The His Optimised Pacing Evaluated for Heart Failure Trial (HOPE-HF).
Acronym
HOPE-HF
Condition
Heart Failure
Intervention (Device)
Pacemaker: AV optimised, His pacing.
Lead sponsor
Imperial College London (class: other)
Collaborator
British Heart Foundation (class: other)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct02671903
Content hash
c5f259d9d5907136e68cd92d7e8cf4d3316fecce239ee8a6c035da5ed8938c11